Selective Histone Deacetylase Inhibitors with Anticancer Activity

Title:Selective Histone Deacetylase Inhibitors with Anticancer Activity

Volume: 16 Issue: 4

Author(s): Nan Ma, Ying Luo, Ying Wang, Chenzhong Liao, Wen-Cai Ye and Sheng Jiang

Affiliation:

Keywords: Class I, Class II, Class III, HDAC, HDAC1, HDAC6, Selective histone deacetylase inhibitors.

Abstract: HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.

Cite this article as:

Ma Nan, Luo Ying, Wang Ying, Liao Chenzhong, Ye Wen-Cai and Jiang Sheng, Selective Histone Deacetylase Inhibitors with Anticancer Activity, Current Topics in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1568026615666150813145629